JP2024505128A - 抗ｃｄ７３抗体の製剤 - Google Patents

抗ｃｄ７３抗体の製剤 Download PDF

Info

Publication number
JP2024505128A
JP2024505128A JP2023540516A JP2023540516A JP2024505128A JP 2024505128 A JP2024505128 A JP 2024505128A JP 2023540516 A JP2023540516 A JP 2023540516A JP 2023540516 A JP2023540516 A JP 2023540516A JP 2024505128 A JP2024505128 A JP 2024505128A
Authority
JP
Japan
Prior art keywords
volume
mass
cancer
results
histidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023540516A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024505128A5 (https=
Inventor
ジン ジュー，
ジェルー ジャン，
シャンピン ジュー，
ヤーリー ユー，
Original Assignee
アイ－エムエービー バイオファーマ カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイ－エムエービー バイオファーマ カンパニー リミテッド filed Critical アイ－エムエービー バイオファーマ カンパニー リミテッド
Publication of JP2024505128A publication Critical patent/JP2024505128A/ja
Publication of JP2024505128A5 publication Critical patent/JP2024505128A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2023540516A 2020-12-30 2021-05-08 抗ｃｄ７３抗体の製剤 Pending JP2024505128A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/141601 2020-12-30
CN2020141601 2020-12-30
PCT/CN2021/092485 WO2022142053A1 (en) 2020-12-30 2021-05-08 Formulations of anti-cd73 antibodies

Publications (2)

Publication Number Publication Date
JP2024505128A true JP2024505128A (ja) 2024-02-05
JP2024505128A5 JP2024505128A5 (https=) 2024-05-17

Family

ID=82258959

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023540516A Pending JP2024505128A (ja) 2020-12-30 2021-05-08 抗ｃｄ７３抗体の製剤

Country Status (8)

Country Link
US (1) US20240101698A1 (https=)
EP (1) EP4271410A4 (https=)
JP (1) JP2024505128A (https=)
KR (1) KR20230127292A (https=)
CN (1) CN116615458A (https=)
AU (1) AU2021415180A1 (https=)
CA (1) CA3203441A1 (https=)
WO (1) WO2022142053A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119744177A (zh) * 2023-07-24 2025-04-01 石药集团巨石生物制药有限公司 重组人源化抗cd73单克隆抗体的药物组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018137598A1 (en) * 2017-01-24 2018-08-02 I-Mab Anti-cd73 antibodies and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SV2007002227A (es) * 2004-09-10 2007-03-20 Wyeth Corp Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina ref. 040000-0317637
JP5933975B2 (ja) * 2008-11-12 2016-06-15 メディミューン，エルエルシー 抗体製剤
CN102413839A (zh) * 2009-03-06 2012-04-11 医学免疫有限责任公司 人源化抗cd19抗体制剂
CN102512384B (zh) * 2011-12-29 2014-11-26 嘉和生物药业有限公司 一种冻干剂型蛋白组合物及其制备方法
MX2018003298A (es) * 2015-09-22 2018-06-20 Pfizer Metodo para preparar una formulacion de proteinas terapeuticas y formulacion de anticuerpos producida por tal metodo.
WO2017189433A1 (en) * 2016-04-25 2017-11-02 Medimmune, Llc Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies
US20210054079A1 (en) * 2018-04-25 2021-02-25 Medimmune Limited Formulations of human anti-pd-li antibodies
WO2020020307A1 (en) * 2018-07-25 2020-01-30 I-Mab Biopharma Co., Ltd. Anti-cd73 anti-pd-l1 bispecific antibodies
CN113286825B (zh) * 2018-11-30 2024-06-18 爱必乐生物公司 抗pd-l1/抗4-1bb双特异性抗体及其用途
CN111686247B (zh) * 2019-03-13 2022-07-29 苏州康乃德生物医药有限公司 包含人白介素-4受体α的抗体的液体组合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018137598A1 (en) * 2017-01-24 2018-08-02 I-Mab Anti-cd73 antibodies and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EUR. J. PHARM. BIOPHARM., vol. 78, JPN6025025820, 2011, pages 208 - 212, ISSN: 0005825097 *
J. PHARM. SCI., vol. 96, no. 1, JPN6025025821, 2007, pages 1 - 26, ISSN: 0005825098 *

Also Published As

Publication number Publication date
WO2022142053A1 (en) 2022-07-07
EP4271410A1 (en) 2023-11-08
AU2021415180A1 (en) 2023-07-06
CA3203441A1 (en) 2022-07-07
KR20230127292A (ko) 2023-08-31
EP4271410A4 (en) 2025-08-13
CN116615458A (zh) 2023-08-18
US20240101698A1 (en) 2024-03-28

Similar Documents

Publication Publication Date Title
JP7653465B2 (ja) 単独およびプログラム死受容体１（ｐｄ－１）抗体と組み合わされた抗ｃｔｌａ４抗体の安定な製剤、ならびにその使用方法
UA128202C2 (uk) Стабільна композиція антитіла до рецептора програмованої загибелі 1 (pd-1) і спосіб її застосування
KR102697026B1 (ko) 항-pd-l1 항체 아벨루맙을 포함하는 수성 약학 제형
CN105163763A (zh) 抗egfr抗体药物偶联物制剂
JP7805289B2 (ja) 抗コネキシン抗体製剤
CN111228479B (zh) 一种抗pd-l1抗体制剂
EP4374874A1 (en) Pharmaceutical composition containing anti-trop2 antibody drug conjugate and use thereof
WO2022128716A1 (en) Pharmaceutical composition comprising a bispecific anti-muc1/egfr antibody-drug conjugate
CA3252354A1 (en) Pharmaceutical composition containing an anti-nectin-4 antibody conjugate and its use
US20190240345A1 (en) Novel stable formulation
JP2024505128A (ja) 抗ｃｄ７３抗体の製剤
KR20240024941A (ko) 항-pd1 항체의 제제
TWI880260B (zh) 抗pd-l1/抗-4-1bb雙特異性抗體製劑
CN116459335A (zh) 抗cldn-18.2抗体药物组合物及其用途
CN116725961A (zh) 抗cd39抗体药物组合物及其用途
CN116172947A (zh) 一种含特异性结合vegf和ang2的双特异性抗体的药物组合物
CN119095618B (zh) 用于治疗巨噬细胞活化综合征的组合物和方法
EP4548931A1 (en) Anti-pcsk9 antibody preparation and use thereof
KR20260058842A (ko) 항-psma adc 접합체 조성물 및 이의 사용 방법
HK40103088A (zh) 抗il5r抗体配制品
TW202432601A (zh) 包含抗人類ｔｓｌｐ受體抗體之醫藥組成物及其使用方法
EA050576B1 (ru) Фармацевтическая композиция, содержащая конъюгат антитело против trop2 - лекарственное средство, и ее применение
HK40077586A (en) Anto-connexin antibody formulations

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240507

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240507

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250625

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260325